Kenvue unveils efficacy of colloidal oatmeal in managing atopic dermatitis in Black children and shares new Neutrogena® product innovations at Science of Skincare Summit

SKILLMAN, N.J.September 21, 2023 - Kenvue Inc. (NYSE: KVUE) ("Kenvue"), the world's largest pure-play consumer health company by revenue, will present its reported findings on oatmeal cream as an effective strategy for relieving atopic dermatitis in Black children. Additionally, Kenvue will share next generation solutions in cleansing and hydration from Neutrogena¹, and present other industry-advancing science at the Science of Skincare Summit scheduled for September 21-23, 2023, at the Hotel Van Zandt in Austin, Texas.

Kenvue will exhibit and participate in sessions throughout the Summit in the Lady Bird Foyer, starting on Thursday, September 21 at 5 p.m. CDT and continuing through the end of the summit. Kenvue experts will also present Aveeno^®[1]and Neutrogena^® science in Booths 6 and 7.

"Kenvue is thrilled to be sharing new data and innovations with leading experts in skincare science, aligning with our mission to realize the extraordinary power of everyday care with products that have the power to both soothe and rejuvenate the skin," said Fabiana Gargaro², Head of Kenvue Global Skin Health R&D. "We consider this summit a critical opportunity to collaborate and connect with dermatologist partners with our science backed and clinically proven skin care solutions."

Industry Theater Sessions On-Site:

The Power of Oat for Sensitive Skin - September 23, 2:00 to 2:15 p.m. CDT, Meriwether

Tonianne Lisante[2], Kenvue Scientific Engagement Manager, will detail the findings of a new peer-reviewed study, in which she is the lead author, published in the Journal of Dermatological Treatment, "A 1% colloidal oatmeal OTC cream is clinically effective for the management of mild to moderate atopic dermatitis in Black or African American children."[3]Lisante will also touch on the use of colloidal oatmeal in a variety of product platforms to strengthen the skin's moisture barrier, sooth irritated skin, and help support the microbiome.

Neutrogena® Hydro Boost: Next Generation Gentle Cleansing and Hydrating Moisturizers - September 23rd 8:15 to 8:30 a.m. CDT, Meriwether

Menas Kizoulis²,Kenvue Senior Director of Global Scientific Engagement, will highlight Neutrogena's^® expertise in creating next-generation solutions for gentle cleansing and hydration that move beyond functional skin care by combining superior aesthetics with dermatologist-validated clinical efficacy and performance.

In addition to highlighting Neutrogena's^® gentle polymeric cleansing technology, Kizoulis will introduce two next-generation Neutrogena^®Hydro Boost formulations for skin hydration. He will share clinical data that shows new Hydro Boost Water Cream delivers 72-hour hydration efficacy and results from a dermatologist-conducted study among subjects with sensitive skin demonstrating it improved skin's visual smoothness in 95% of participants and skin radiance in 87% of participants. He will also address the uniqueness of the Hydro Boost platform of skincare solutions for individuals with sensitive skin due to eczema, rosacea, or the use of topical acne medications.

Additionally, Barbara Green², RPh, MS, Kenvue Senior Director for Face Skincare Product Innovation will be participating in a panel session:

Targeting Cell Senescence: Next Frontier - September 22nd 2:00 to 2:30 p.m. CDT, Lady Bird Ballroom II-III

Green will participate in a panel covering formulation strategies that address the impact of cellular senescence on the aging of skin across various populations, including those affected by pre-aging. She will discuss new research focused on promoting the health and beauty of the pre-aging population through an understanding of age-specific cellular vulnerabilities and the use of effective topical skincare approaches, including antioxidants, sunscreens, and retinol.

Exploring the Findings and Importance of the Colloidal Oatmeal Study

Black children are 1.7 times more likely to develop eczema than White children, and while colloidal oatmeal is the only OTC skin protectant indicated by the U.S. Food & Drug Administration (FDA) for the relief of eczema symptoms such as itch and minor skin irritations, there is a lack of clinical evidence for its use or other potential solutions in this population.

"When products are not tested in a diverse population, there is a reluctance to accept them as solutions," Lisante said. "A previously published randomized study, conducted in children with atopic dermatitis, also known as eczema, the most common chronic inflammatory skin disease, had already established the safety and efficacy of an OTC 1% colloidal oatmeal cream versus a ceramide-based prescription barrier cream in relieving eczema symptoms in children with mild to moderate eczema. Interestingly, the diverse population included in this study provided a new opportunity to conduct a sub analysis among the group of Black subjects, who we know are more effected by eczema, to help advance community health and solve for public health challenges."

Overall, Lisante's publication showed that among the Black subjects, after three weeks of treatment with an OTC moisturizer containing 1% colloidal oatmeal, at least twice daily, Eczema Area and Severity Index scores in the colloidal oatmeal versus the prescription ceramide barrier cream groups improved by 2.4 and 2.1 points, respectively.

The sub analysis can be viewed here: https://www.tandfonline.com/doi/full/10.1080/09546634.2023.2241587

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development of Aveeno^® andNeutrogena^®. Forward-looking statements may be identified by the use of words such as "plans," "expects," "will," "anticipates," "estimates" and other words of similar meaning. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kenvue Inc. ("Kenvue") and its affiliates.

A list and descriptions of risks, uncertainties and other factors can be found in Kenvue's filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and subsequent Quarterly Reports on Form 10-Q and other filings, available at www.kenvue.com or on request from Kenvue. Kenvue and its affiliates undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or developments or otherwise

Contact:
Media relations
[email protected]

[1]Neutrogena and Aveeno are brands of Johnson & Johnson Consumer Inc., a subsidiary of Kenvue.

[2]Tonianne Lisante, Menas Kizoulis, Barbara Green, and Fabiana Gargaro are employees of Johnson & Johnson Consumer Inc.

[3]Lisante TA, Kizoulis M, Nunez C, Hartman CL. A 1% colloidal oatmeal OTC cream is clinically effective for the management of mild to moderate atopic dermatitis in Black or African American children. Journal of Dermatological Treatment. Published online August 18, 2023. https://doi.org/10.1080/09546634.2023.2241587.

Public link

Please use the above public link if you want to share this noodl on another website.